Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Bradenton, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Ft. Lauderdale, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Gainesville, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Kissimmee, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Kissimmee, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Leesburg, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Leesburg, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Oakland Park, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Oakland Park, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Orlando, FL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Atlanta, GA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Decatur, GA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Chicago, IL
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Lake Charles, LA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Lake Charles, LA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Shreveport, LA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Rockville, MD
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Flowood, MS
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Flowood, MS
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Creve Couer, MO
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Creve Couer, MO
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
St. Louis, MO
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Marlton, NJ
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Marlton, NJ
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Neptune, NJ
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Neptune, NJ
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Canton, OH
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes' Investigational Study Site
mi
from
Mason, OH
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes' Investigational Study Site
mi
from
Mason, OH
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Oklahoma City, OK
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Oklahoma City, OK
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Philadelphia, PA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Charleston, SC
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Memphis, TN
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Austin, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Study Site
mi
from
Austin, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Study Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Dallas, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Dallas, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Desoto, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Desoto, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Houston, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Houston, TX
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Salt Lake City, UT
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Bellvue, WA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Bellvue, WA
Click here to add this to my saved trials
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated:  3/21/2014
Alkermes Investigational Site
mi
from
Richland, WA
A Study of ALKS 3831 in Adults With Schizophrenia
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Status: Enrolling
Updated: 3/21/2014
Alkermes Investigational Site
mi
from
Richland, WA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Intergrated Medical and Behavioral Associates
mi
from
Glendale, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Affiliated Research Institute
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Scientific Clinical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Alexian Brothers Behavioral Health
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CBH Health LLC
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
CRI Worldwide, LLC
mi
from
Willingboro, NJ
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Carolina Clinical Trials, Inc.
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
Vanderbilt Psychiatric Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
FutureSearch Clinical Trials LP
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
InSite Clinical Research LLC
mi
from
DeSoto, TX
Click here to add this to my saved trials
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated:  3/28/2014
mi
from
Arkhangelsk,
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
A Randomized Double-Blind Placebo-Controlled 12-Week Phase 2 Study of Two Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist(EVP-6124)or Placebo in Schizophrenia Subjects on Chronic Stable Atypical Anti-Psychotic Therapy
Status: Enrolling
Updated: 3/28/2014
mi
from
Arkhangelsk,
Click here to add this to my saved trials